IGC Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
IGC Pharma, Inc. (IGC), a Maryland corporation trading on NYSE American under the symbol "IGC," filed this Current Report on Form 8-K dated January 5, 2026. The filing reports the entry into a material definitive agreement regarding a registered direct offering of common stock.
Key Financial Metrics
This filing details a specific capital raise event rather than periodic financial performance. Key metrics associated with the transaction include:
- Shares Issued: 779,997 shares of Common Stock.
- Purchase Price: $0.30 per share.
- Gross Proceeds: Approximately $234,000.
- Net Proceeds: Not specified; gross proceeds are before estimated offering expenses.
- Use of Proceeds: Working capital, general corporate purposes, clinical development programs, and research and development activities.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as of the reporting date.
Material Changes
The primary material change is the execution of the "2025 Subscription Agreement" with certain investors. This agreement facilitates the issuance of new equity, increasing the company's share count and cash reserves pending closing. The closing is expected to occur on or about January 5, 2026, subject to customary conditions.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to fund clinical development and R&D activities. The offering is conducted pursuant to an effective shelf registration statement (Form S-3, File No. 333-276330) declared effective on January 8, 2024. No specific forward-looking guidance, risk factors, or contingencies beyond the standard closing conditions were detailed in this specific excerpt.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $234,000 gross proceeds receipt.
- Review the full text of the Subscription Agreement (Exhibit 10.1) for specific investor identities and any restrictive covenants.
- Confirm the exact amount of offering expenses to determine the actual net proceeds available for operations.
- Check subsequent filings for the updated share count and any dilution impact on existing shareholders.